Fei Xiao1, Chenglong Wang1, Jianping Peng1, Xing Zhou2, Ding Ma1, Yu Wang3, Yanpeng Li4, Xiaodong Chen1, Chuandong Wang1. 1. Department of Orthopedic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, China. 3. Department of Cardiology, Shidong Hospital, Shanghai, China. 4. Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Jining, China.
Abstract
OBJECTIVE: Osteoarthritis (OA) is characterized by the chronic and progressive deterioration of articular cartilage. Chondrocyte senescence could lead to a shift in the balance between extracellular matrix (ECM) component synthesis and degradation. Small noncoding RNAs (sncRNAs), including microRNAs (miRNAs), P-element-induced wimpy testis-(PIWI-) interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), and repeat-associated siRNAs (rasiRNAs), are a class of important epigenetic molecules. We aimed to gain insights into the changes and roles of sncRNA in chondrocyte senescence. DESIGN: Healthy mouse postnatal chondrocytes were isolated, and a replicative aging model was constructed. We used small RNA sequencing (small RNA-seq) to generate extensive small RNA data. We identified differentially expressed sncRNAs and performed tissue-specific analysis using real-time quantitative polymerase chain reaction (qRT-PCR). β-galactosidase staining was used to detect chondrocyte senescence. The results showed that the expression profiles of sncRNA in passage 5 chondrocytes were significantly different from those in passage 0 chondrocytes. The expression of sncRNA was tissue specific. We found that 40 miRNAs were upregulated and 70 miRNAs were downregulated during chondrocyte senescence, and that miR-132-5p expression inhibition prevented chondrocyte senescence. We found that 8 piRNAs were upregulated and 17 piRNAs were downregulated during chondrocyte senescence, and that piRNA piR_025576 overexpression delayed chondrocyte senescence. We found that 24 snoRNAs were upregulated and 28 snoRNAs were downregulated during chondrocyte senescence, and that snoRNA ENSMUSG00000087935 overexpression delayed chondrocyte senescence. We found that 5 snRNAs were upregulated and 6 snRNAs were downregulated during chondrocyte senescence, and that snRNA ENSMUSG00000064682 overexpression delayed chondrocyte senescence. We found that 1 rasiRNA was upregulated and 4 rasiRNAs were downregulated during chondrocyte senescence. CONCLUSIONS: These findings might provide novel insights into OA pathogenesis and contribute to the development of candidates for targeted therapeutics in OA.
OBJECTIVE: Osteoarthritis (OA) is characterized by the chronic and progressive deterioration of articular cartilage. Chondrocyte senescence could lead to a shift in the balance between extracellular matrix (ECM) component synthesis and degradation. Small noncoding RNAs (sncRNAs), including microRNAs (miRNAs), P-element-induced wimpy testis-(PIWI-) interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), and repeat-associated siRNAs (rasiRNAs), are a class of important epigenetic molecules. We aimed to gain insights into the changes and roles of sncRNA in chondrocyte senescence. DESIGN: Healthy mouse postnatal chondrocytes were isolated, and a replicative aging model was constructed. We used small RNA sequencing (small RNA-seq) to generate extensive small RNA data. We identified differentially expressed sncRNAs and performed tissue-specific analysis using real-time quantitative polymerase chain reaction (qRT-PCR). β-galactosidase staining was used to detect chondrocyte senescence. The results showed that the expression profiles of sncRNA in passage 5 chondrocytes were significantly different from those in passage 0 chondrocytes. The expression of sncRNA was tissue specific. We found that 40 miRNAs were upregulated and 70 miRNAs were downregulated during chondrocyte senescence, and that miR-132-5p expression inhibition prevented chondrocyte senescence. We found that 8 piRNAs were upregulated and 17 piRNAs were downregulated during chondrocyte senescence, and that piRNA piR_025576 overexpression delayed chondrocyte senescence. We found that 24 snoRNAs were upregulated and 28 snoRNAs were downregulated during chondrocyte senescence, and that snoRNA ENSMUSG00000087935 overexpression delayed chondrocyte senescence. We found that 5 snRNAs were upregulated and 6 snRNAs were downregulated during chondrocyte senescence, and that snRNA ENSMUSG00000064682 overexpression delayed chondrocyte senescence. We found that 1 rasiRNA was upregulated and 4 rasiRNAs were downregulated during chondrocyte senescence. CONCLUSIONS: These findings might provide novel insights into OA pathogenesis and contribute to the development of candidates for targeted therapeutics in OA.
Entities:
Keywords:
RasiRNAs; chondrocyte senescence; miRNA; piRNA; small nuclear RNAs; small nucleolar RNAs
Osteoarthritis (OA) is a prevalent multiple factor-associated disorder that is
characterized by chronic and progressive deterioration of articular cartilage.
Several risk factors for the development of OA exist, including prior joint injury,
obesity, diabetes mellitus, hyperglycemia, and anatomical factors related to joint
shape and alignment; however, the most prevalent risk factor is increasing
age.[1-3] Cellular senescence, one of the
hallmarks of aging, is a form of irreversible cellular arrest characterized by
senescence-associated beta-galactosidase (SA-β-Gal) activity and the release of
harmful proinflammatory molecules, growth factors, and matrix metalloproteinases as
part of the senescence-associated secretory phenotype (SASP).
As the accumulation of senescent cells reduces cellular proliferation and
disordered tissue function and metabolism, senescence has been implicated in the
pathogenesis and/or progression of a variety of aging-associated diseases, including
OA.[3,5]Although OA has recently been regarded as a whole joint disease rather than merely
dysfunctional cartilage, chondrocytes are primarily known to have a major role in
the pathology of OA.[5-8] Chondrocytes, the unique
resident cell type in articular cartilage, regulate anabolic and catabolic pathways
to maintain cartilage homeostasis. The senescence of chondrocytes is expected to
lead to a shift in the balance between extracellular matrix (ECM) component
synthesis and degradation through metalloproteinase components (i.e., MMP1, MMP2,
MMP3, MMP10, MMP13, and more) of the SASP response.[5,9] There was a causal relationship
between the occurrence and development of OA, which was significantly correlated
with age and chondrocyte aging, but the more specific pathological mechanism has not
been fully clarified. Studies have also confirmed that the expression of SA-β-Gal in
articular cartilage is positively correlated with the severity of OA.
The increase in the positive rate of aging chondrocytes reduced the repair
ability of cartilage, aggravated cartilage degeneration, and led to an increase in
the incidence rate of OA. Understanding the molecular mechanism of chondrocyte aging
is of great significance for the treatment of OA and the development of new
therapies.The exact mechanisms through which senescence can affect cartilage health remain
elusive, although it is believed to be caused by multiple molecular mechanisms
rather than a single etiology. Recent studies have shown that small noncoding RNAs
(sncRNAs), a class of important epigenetic regulatory molecules, play an important
role in regulating cellular senescence in OA.[11-14] SncRNAs are short RNA
species, typically fewer than 200 nucleotides in length, that are not translated
into proteins but have other structural or regulatory biological roles.
These include microRNAs (miRNAs), small nuclear RNAs (snRNAs), small
nucleolar RNAs (snoRNAs), P-element-induced wimpy testis (PIWI-)-interacting RNAs
(piRNAs), small interfering RNAs (siRNAs), transfer RNAs (tRNAs), and
repeat-associated siRNAs (rasiRNAs). SncRNAs are promising candidates for targeted
therapeutics in OA due to their small size, and their activity can be modulated via
small molecules and biological delivery systems.[15,16]In the present study, primary mouse chondrocytes were isolated and subjected to 5
additional passages to simulate chondrocyte replicative senescence in
vitro. To gain insights into sncRNA changes in chondrocyte senescence,
we used small RNA sequencing (small RNA-seq) to generate extensive small RNA data.
We identified differentially expressed sncRNAs and performed tissue-specific
analysis. These findings might provide novel insight into OA pathogenesis and
contribute to the development of candidates for targeted therapeutics in OA.
Materials and Methods
Cell Isolation and Culture
Mouse primary articular chondrocytes were isolated from the femoral heads,
femoral condyles, and tibial plateaus of mice at postnatal day 5 as previously described.
The animal study was reviewed and approved by the Ethics Committee of
Xinhua Hospital affiliated with Shanghai Jiao Tong University School of
Medicine. Cartilage was minced into small pieces. After digestion with 0.25%
trypsin and collagenase D solution at 0.5 mg/ml, chondrocytes were collected and
cultured in Dulbecco’s modified Eagle medium DMEM (1 g glucose per ml; Sigma,
cat. no. D5546) supplemented with 10% fetal bovine serum (FBS) (Gibco, Thermo
Fisher Scientific, USA) and 1% penicillin-streptomycin. Chondrocytes at passages
0 to 5 were used in all experiments.
SA-β-Gal Staining
The Senescence Detection Kit (BioVision, San Francisco, CA, USA) was used to
stain SA-β-Gal. Chondrocytes at passages 1 and 5 were rinsed in
phosphate-buffered saline (PBS). After fixation with fixative solution at room
temperature for 15 minutes, the cells were washed twice with PBS. Next, the
cells were added to a staining solution mixture and incubated overnight at 37°C.
Chondrocytes were then washed twice with PBS, and the senescent cells stained
blue were analyzed under a light microscope.
qRT-PCR Analysis
Total RNA was extracted from cells using an RNeasy Mini kit (Qiagen, Valencia,
CA, USA) according to the manufacturer’s instructions, and cDNA was synthesized
from total RNA (1 µg) using reverse transcriptase (TaKaRa Biotechnology, Otsu,
Japan). The complementary DNA (cDNA; 10 ng) products were used as the template
for amplification using SYBR Green PCR Master Mix (TaKaRa Biotechnology).
Furthermore, mRNA expression was detected by an ABI 7500 sequencing detection
system (Applied Biosystems, Foster City, CA, USA). The primer lists are shown in
Supplementary Material S1.
Small RNA-Seq
The original image data file obtained by high-throughput sequencing was
transformed into the original sequenced reads by base calling analysis. The
results are stored in FASTQ (FQ) file format, which contains the sequence
information of sequenced reads and their corresponding sequencing quality
information. First, the original data were preprocessed, joint sequences were
removed, low-quality sequences were filtered, and then the FASTQ format was
converted to a FASTA format. After data preprocessing, we used Bowtie software
to compare the sequences to the reference genome, and only the sequences aligned
to the reference genome were selected for subsequent analysis. To
comprehensively predict noncoding RNAs of different lengths, we first extracted
the sequencing sequences aligned to the reference genome in each sample and then
clustered the sequences of all samples using cd-hit to remove the same or
similar sequences. Then, we used infernal software to search the RFAM database.
After searching, we matched the small RNA sequence in the RFAM database and then
compared the sequencing data of each sample to count the read count of small RNA
of each sample. The read count was additionally subjected to TPM standardization
to calculate the proportion of each million reads in the comparison. For the
experiments with biological repetition, we used DESeq for the analysis. For
experiments without biological duplication, we used edger for the analysis.
Finally, the genes with Padj less than 0.05 and a difference multiple greater
than or equal to 2 were selected as small RNAs with significant differential
expression.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 24, and graphs were
generated by GraphPad Prism 9. Independent sample t tests were
used to analyze the mRNA expression results from the qPCR assays. P
values less than 0.05 were considered significant.
Results
Elevation of Cell Senescence with Increasing Passages
First, the morphological changes in the chondrocytes were recorded. Mouse
cartilage chondrocytes were isolated and continuously subcultured to passage 5.
At passage 1, chondrocytes had a characteristic tetris-shaped, smooth cell
surface, and grew regularly. Unlike the cells at passage 1, almost all
chondrocytes at passage 5 exhibited irregular shapes with pseudopods and became
larger and flatter (
). The SA-β-Gal activity test is usually performed for the identification
of senescent cells. The senescence status of chondrocytes at passage 5 was
confirmed by the SA-β-Gal staining assay, which showed increased lysosomal
β-galactosidase activity specifically in senescent cells (
). To further evaluate senescence at the molecular level, the mRNA
expression levels of the cellular senescence-related proteins Sirt1, p16, p21,
and p53 were detected at different passages. The mRNA expression of Sirt1, p16,
p21, and p53 also showed increasing trends as the passage number increased (
). The proliferation rate of chondrocytes at passage 5 was significantly
decreased compared with that of chondrocytes at passage 1 (
). These results suggest that chondrocytes undergo replicative senescence
during in vitro amplification.Elevation of cell senescence with increasing passages. (A)
The morphology of chondrocytes at passages 1 and 5. The scale bar
represents 100 μm. (B) β-Gal staining of chondrocytes at
passages 1 and 5. The scale bar represents 100 μm. Real-time
quantitative polymerase chain reaction analysis of the mRNA expression
of Sirt1 (C), p16 (D), p21 (E),
and p53 (F) in chondrocytes from passages 1 to 5.
(C) CCK-8 detected the cell viability of chondrocytes
at passages 1 and 5. CCK-8 = Cell Counting Kit-8. ** indicates
P < 0.01 compared to passage 1.
Identification of Differentially Expressed miRNAs and Tissue-Specific
Analysis
As important epigenetic regulators, miRNAs bind to specific regions of target
mRNAs, resulting in reduced protein expression and thus participating in many
cellular processes. We performed small RNA-seq to analyze the miRNA expression
profiling change in replicative senescence chondrocytes. The small RNA-seq
results showed that 40 miRNAs were upregulated and 70 miRNAs were downregulated
in chondrocytes at passage 5 compared with those at passage 0 (
). Then, we further verified the expression of several miRNAs with the
greatest difference in the sequencing results using qRT-PCR. Consistent with the
sequencing results, the qRT-PCR results showed that the expression of
miR-145a-3p, miR-132-5p, miR-34b-5p, miR-145a-5p, miR-34c-5p and miR-129-3p was
increased in chondrocytes at passage 5 compared with that at passage 0 (
). Moreover, the expression of miR-503-5p, miR-675-3p, miR-542-5p,
miR-182-5p, and miR-130b-5p was decreased in chondrocytes at passage 5 compared
with that at passage 0 (
). We also detected the expression of miR-145a-3p, miR-132-5p,
miR-503-5p, and miR-675-3p in different mouse tissues (
). β-galactosidase staining showed that inhibiting the expression of
miR-132-5p in chondrocytes could effectively inhibit the aging of chondrocytes (
).Identification of differentially expressed miRNAs and tissue-specific
analysis. (A) Heatmap showing the differentially expressed
miRNAs between chondrocytes at passages 1 and 5. (B) MA
showing the differentially expressed miRNAs between chondrocytes at
passages 1 and 5. (C) Volcano plot showing the
differentially expressed miRNAs between chondrocytes at passages 1 and
5. (D) Principal component analysis showing the
differentially expressed miRNAs between chondrocytes at passage 1 and
passage 5. (E) qRT-PCR analysis of miRNA expression in
chondrocytes at passage 1 compared to that at passage 5.
(F) qRT-PCR analysis of miRNA expression in chondrocytes
within passage 1 compared to that at passage 5. qRT-PCR analysis of
(G) mmu-miR-145a-3p, (H) mmu-miR-132-5p,
(I) mmu-miR-503-5p, and (J) mmu-miR-675-3p
in different tissues. (K) β-Gal staining of chondrocytes at
passage 5 with miRNA inhibitor NC or miR-132-5p inhibitor. qRT-PCR =
real-time quantitative polymerase chain reaction; MA = minus-average; NC
= negative control; CPM = count per million; PCA = principle component
Analysis. **indicates P < 0.01 compared to passage
1.
Identification of Differentially Expressed piRNAs and Tissue-Specific
Analysis
Compared with miRNAs, piRNAs are a relatively new type of sncRNA and have
attracted increasing attention in recent years. piRNAs, which have a length of
24-31 nucleotides, play regulatory roles, such as silencing the transcriptional
gene process, regulating mRNA stability, interacting with multiple proteins, and
maintaining stem cell functions.
We performed small RNA-seq to analyze piRNA expression profiling changes
in chondrocytes undergoing replicative senescence. The small RNA-seq results
showed that 8 piRNAs were upregulated and 17 piRNAs were downregulated in
chondrocytes at passage 5 compared with those at passage 0 (
). Principal components analysis (PCA) showed that the aging of
chondrocytes was closely related to the expression of piRNAs (
). Then, we further verified the expression of the differentially
expressed piRNAs using qRT-PCR. Consistent with the sequencing results, the
qRT-PCR results showed that the expression of piR_022877, piR_000580,
piR_025007, and piR_025576 was decreased in chondrocytes at passage 5 compared
with those at passage 0 (
). However, no piRNA was verified to be upregulated in chondrocytes at
passage 5 using qRT-PCR. We also detected the expression of piR_022877,
piR_000580, piR_025007, and piR_025576 in different mouse tissues (
). β-galactosidase staining showed that piRNA piR_025578 overexpression
in chondrocytes could effectively inhibit the aging of chondrocytes (
).Identification of differentially expressed piRNAs and tissue-specific
analysis. (A) Heatmap showing the differentially expressed
piRNAs between chondrocytes at passages 1 and 5. (B) MA
showing the differentially expressed piRNAs between chondrocytes at
passages 1 and passage 5. (C) Scatter plot showing the
differentially expressed piRNAs between chondrocytes at passages 1 and
5. (D) Volcano plot showing the differentially expressed
piRNAs between chondrocytes at passages 1 and 5. (E)
Principal components analysis showing the differentially expressed
piRNAs between chondrocytes at passages 1 and 5. (F)
qRT-PCR analysis of piRNA expression in chondrocytes within passage 1
compared to that at passage 5. qRT-PCR analysis of (G)
mmu_piR_022877, (H) mmu_piR_000580, (I)
mmu_piR_025007, and (J) mmu_piR_025576 in different
tissues. (K) β-Gal staining of chondrocytes at passage 5
with piRNA mimics NC or piR_025576 mimics. qRT-PCR = real-time
quantitative polymerase chain reaction; MA = minus-average; pLVX =
plasmid lentiviral vector X; CPM = count per million; PCA = principle
component analysis. * indicates P < 0.05 and **
indicates P < 0.01 compared to passage 1.
Identification of Differentially Expressed snoRNAs and Tissue-Specific
Analysis
SnoRNAs direct chemical modification of other RNA substrates to fine-tune
spliceosomal splicing and are mainly involved in endoribonucleolytic pre-rRNA processing.
The role of snoRNAs in cartilage aging has attracted increasing attention.
We performed small RNA-seq to analyze the snoRNA expression profiling
change in replicative senescent chondrocytes. The small RNA-seq results showed
that 24 snoRNAs were upregulated and 28 snoRNAs were downregulated in
chondrocytes at passage 5 compared with those at passage 0 (
). PCA showed that the aging of chondrocytes was closely related to the
expression of snoRNA (
). Then, we further verified the expression of several snoRNAs with
significant differences in the sequencing results using qRT-PCR. Consistent with
the sequencing results, the qRT-PCR results showed that the downregulated
snoRNAs were decreased in chondrocytes at passage 5 compared with those at
passage 0 (
). However, only ENSMUSG00000065904 was verified to be upregulated, which
was consistent with the sequencing results. The other 16 snoRNAs with
upregulated sequencing results were verified to have decreased expression (
). We also detected the expression of ENSMUSG00000087935,
ENSMUSG00000077604, ENSMUSG00000095205, and ENSMUSG00000065272 in different
mouse tissues (
). β-galactosidase staining showed that overexpression of the snoRNA
ENSMUSG00000087935 in chondrocytes effectively inhibited the aging of
chondrocytes (
).Identification of differentially expressed snoRNAs and tissue-specific
analysis. (A) Heatmap showing the differentially expressed
snoRNAs between chondrocytes at passages 1 and 5. (B) MA
showing the differentially expressed snoRNAs between chondrocytes at
passages 1 and 5. (C) Volcano plot showing the
differentially expressed snoRNAs between chondrocytes at passages 1 and
5. (D) Principal component analysis showing the
differentially expressed snoRNAs between chondrocytes at passages 1 and
5. (E) qRT-PCR analysis of snoRNA expression in
chondrocytes at passage 1 compared with that at passage 5.
(F) qRT-PCR analysis of snoRNA expression in
chondrocytes at passage 1 compared with that at passage 5. qRT-PCR
analysis of (G) ENSMUSG00000087935, (H)
ENSMUSG00000077604, (I) ENSMUSG00000095205, and
(J) ENSMUSG00000065272 in different tissues.
(K) β-Gal staining of chondrocytes at passage 5 with
pLVX-Vecotor or pLVX-ENSMUSG00000087935. qRT-PCR = real-time
quantitative polymerase chain reaction; MA = minus-average; pLVX =
plasmid lentiviral vector X; CPM = count per million; PCA = principle
component analysis. * indicates P < 0.05 and **
indicates P < 0.01 compared with passage 1.
Identification of Differentially Expressed snRNAs and Tissue-Specific
Analysis
SnRNA is the main component of RNA spliceosomes in the posttranscriptional
processing of eukaryotes, with a length of 100-215 nucleotides. At present,
there is no literature on snRNAs directly related to chondrocytes or cartilage.
We performed small RNA-seq to analyze the snRNA expression profiling change in
chondrocytes undergoing replicative senescence. The small RNA-seq results showed
that 5 snRNAs were upregulated and 6 snRNAs were downregulated in chondrocytes
at passage 5 compared with those at passage 0 (
). PCA showed that the aging of chondrocytes was closely related to the
expression of snoRNA (
). Then, we further verified the expression of several snRNAs with
significant differences in the sequencing results using qRT-PCR. Consistent with
the sequencing results, the qRT-PCR results showed that the expression of nine
snRNAs was decreased and the expression of one snRNA was increased in
chondrocytes at passage 5 compared with those at passage 0 (
). The expression of ENSMUSG00000064923, ENSMUSG00000064403,
ENSMUSG00000065794, and ENSMUSG00000065773 was consistent with the sequencing
results. We also detected the expression of ENSMUSG00000094655,
ENSMUSG00000064682, ENSMUSG00000087754, and ENSMUSG00000064923 in different
mouse tissues (
). β-galactosidase staining showed that snRNA ENSMUSG00000064682
overexpression in chondrocytes could effectively inhibit the aging of
chondrocytes (
).Identification of differentially expressed snRNAs and tissue-specific
analysis. (A) Heatmap showing the differentially expressed
snRNAs between chondrocytes at passages 1 and 5. (B) MA
showing the differentially expressed snRNAs between chondrocytes at
passages 1 and 5. (C) Scatter plot showing the
differentially expressed snRNAs between chondrocytes at passages 1 and
5. (D) Volcano plot showing the differentially expressed
snRNAs between chondrocytes at passages 1 and 5. (E)
Principal components analysis showing the differentially expressed
snRNAs between chondrocytes at passages 1 and 5. (F)
qRT-PCR analysis of snRNA expression in chondrocytes at passage 1
compared with that at passage 5. qRT-PCR analysis of (G)
ENSMUSG00000094655, (H) ENSMUSG00000064682,
(I) ENSMUSG00000087754, and (J)
ENSMUSG00000064923 in different tissues. (K) β-Gal staining
of chondrocytes at passage 5 with pLVX-Vecotor or
pLVX-ENSMUSG000000648682. qRT-PCR = real-time quantitative polymerase
chain reaction. * indicates P < 0.05 and **
indicates P < 0.01 compared with passage 1.
Identification of Differentially Expressed rasiRNAs
RasiRNAs of 24-28 nucleotides in length may assume a role in sperm confrontation
and consolidation.
Unfortunately, there are no studies in the literature focusing on repeat
RNAs that are directly related to chondrocytes or cartilage. We performed small
RNA-seq to analyze the repeat RNA expression profiling change in replicative
senescent chondrocytes. The small RNA-seq results showed that only one repeat
RNA was upregulated, and 4 repeat RNAs were downregulated in chondrocytes at
passage 5 compared with passage 0 (
). PCA showed that the aging of chondrocytes was closely related to the
expression of rasiRNA (
). There was no significant difference in total rasiRNA count per million
(CPM) in senescent chondrocytes (
).Identification of differentially expressed rasiRNAs and tissue-specific
analysis. (A) Heatmap showing the differentially expressed
rasiRNAs between chondrocytes at passages 1 and 5. (B) MA
showing the differentially expressed rasiRNAs between chondrocytes at
passages 1 and 5. (C) Scatter plot showing the
differentially expressed rasiRNAs between chondrocytes at passages 1 and
5. (D) Volcano plot showing the differentially expressed
rasiRNAs between chondrocytes at passages 1 and 5. (E)
Principal components analysis showing the differentially expressed
rasiRNAs between chondrocytes at passages 1 and 5. (F) CPM
violin plot showing the differentially expressed rasiRNAs between
chondrocytes at passages 1 and 5. MA =Minus-Average, NC = Negative
control, CPM = Count per million, PCA = Principle Component
Analysis.
Discussion
Cellular senescence is a driver of various aging-associated disorders, including OA.
OA chondrocytes exhibit features that are similar to senescent cells, such as
specific senescent markers, telomere shortening, and increased SA-β Gal
activity.[21,22] Exploring anti-cellular senescence strategies may be a
promising approach to prevent or cure OA. The exact mechanism of chondrocyte
senescence remains elusive, although two different mechanisms of senescence have
been suggested in chondrocytes, including stress-induced premature senescence (SIPS)
and replicative senescence.[23,24] It was concluded that replicative senescence contributes to
either the development or the progression of OA.SncRNAs, a large class of regulatory molecules, are involved in organism development
and coordination of biological processes, including metabolism, maintaining genome
integrity, and immune and stress responses.
Recent studies have suggested that sncRNAs play an important role in
regulating cellular senescence in OA.[11-14] The aim of this study was to
systematically investigate the sncRNA profile changes in senescent chondrocytes
after long-term expansion in vitro. We found that mouse
chondrocytes at passage 5 showed obvious senescence characteristics, including
increased SA-β Gal activity and senescence-related gene expression. Moreover, the
expression profiles of miRNAs, snRNAs, snoRNAs, piRNAs, and rasiRNAs in passage 5
chondrocytes were significantly different from those in passage 0 chondrocytes.MiRNAs, the most studied sncRNAs, exert their negative regulatory functions by
partially or fully binding complementary sequences in the 3ʹ untranslated region of
their messenger RNA (mRNA) targets, thus inhibiting mRNA translation. Our results
showed that 6 miRNAs were upregulated and 5 miRNAs were downregulated (
and H). Some differentially expressed miRNAs have been reported
to be related to chondrocyte metabolism or cellular senescence. For example,
miR-145a-3p and miR-145a-5p were upregulated at passage 5. It has been reported that
miR-145 contributes to impaired ECM in OA cartilage in part by targeting Smad3
and negatively regulates tumor necrosis factor (TNF)-α-mediated signaling
activation and the induction of cartilage matrix degradation mechanically through
the MKK4-JNK/p38-c-Jun/ATF2 axis during OA pathogenesis.
In addition, miR-145 plays a role in regulating cellular senescence; for
example, miR-145 induces the senescence of activated hepatic stellate cells through
the activation of the p53 pathway by ZEB2.
The expression of miR-145a-3p in the saliva of patients with Parkinson’s
disease, which is an aging-related disease, was significantly increased.
The expression of miR-34b-5p in aged skin was significantly increased, and
the overexpression of miR-34b-5p in skin fibroblasts resulted in cell cycle arrest.
MiR-34b-5p plays an important role in the process of mouse vascular aging.
On the other hand, miR-34b-5p may be a biomarker for poststroke social
isolation of aged mice.
MiR-34c-5p promoted ultraviolet irradiation-induced senescence of epidermal fibroblasts.
MiR-34c-5p inhibits the progression of leukemia by inducing the senescence of
myeloid leukemia stem cells.
MiR-145a-3p, miR-34b-5p, and miR-34c-5p were also highly expressed in aging
chondrocytes. A recent study suggested that miR-503-5p was downregulated in the
cartilage tissues of OA patients compared with normal people and that HDAC2 could
promote OA through the miR-503-5p/SGK1 axis, while overexpression of miR-503-5p
resulted in promoted proliferation and reduced apoptosis of rat primary chondrocytes.
In addition, miR-675-3p expression levels were significantly decreased in OA
patient cartilage and interleukin (IL)-1β-treated chondrocytes, while overexpression
of miR-675-3p inhibited IL-1β-stimulated apoptosis, matrix degradation and
inflammation in chondrocytes by targeting GNG5.
The results of the present study showed that the expression of miR-503-5p
decreased in senescent chondrocytes, which implies that miR-503-5p might play an
important role in regulating chondrocyte senescence. Since the function of the other
differentially expressed miRNAs in senescent chondrocytes remains unclear, further
studies are needed.PiRNAs are a type of small RNA with a length of approximately 24-13 nucleotides. The
precursors of piRNAs are derived from tandem repeat sequences called piRNA clusters
and form a mature piRNA/PIWI complex via two route-dependent or independent
“Ping-Pong” amplification pathways.
In the past, piRNAs were thought to exist only in the reproductive system to
regulate the growth and development of germ cells. Recently, it was reported that
piRNAs are also expressed in several other human tissues with tissue specificity.
PiRNAs play roles in transcriptional or posttranscriptional gene silencing
pathways by combining Piwi subfamily proteins to form piRNA complexes. At present,
piRNA research mainly focuses on its regulation of the occurrence and development of
cancer, including colorectal cancer, breast cancer and lung cancer.
To our knowledge, there are no reports on the relationship between piRNAs and
OA or cartilage, and the role of piRNAs in chondrocytes is unknown. Our results
showed that the expression of piR_022877, piR_000580, piR_025007, and piR_025576 was
decreased in chondrocytes at passage 5 compared with passage 0, while no piRNA was
verified to upregulate piR_022877, piR_000580, piR_025007, and piR_025576 (
). An increasing number of epigenetic studies have shown that epigenetic
regulation of gene expression plays an important role in the pathological mechanism
of chondrocyte aging and OA.
The aging process of OA chondrocytes involves an increase in the expression
of a variety of matrix-degrading enzymes. The demethylation of the promoter sites of
various matrix-degrading enzymes, such as MMP-3, MMP-9, and ADAMTS-4, is related to
their enhanced expression in OA.
PiRNA is involved in the regulation of DNA methylation.
PiRNA-823 promotes the proliferation of myeloma by regulating DNA methylation.
PiRNA-6426 promotes the methylation of SOAT1 and heart repair.
We also detected piRNAs in multiple tissues or organs (
), although their specific functions need to be further elucidated. The
results showed that piR_000580 and piR_025576 were highly expressed in cartilage and
may be involved in the regulation of DNA methylation modification in
chondrocytes.SnoRNAs, a class of evolutionarily conserved noncoding small guide RNAs with lengths
of 60-300 nucleotides, are extensively studied noncoding RNAs that primarily
accumulate in the nucleoli.
SnoRNAs are involved in the direct chemical modification of other RNA
substrates and the regulation of alternative splicing and posttranscriptional
modification of snRNA, tRNA, and mRNA, while others exhibit miR-like activity.
Recently, snoRNAs have been increasingly studied in aging and OA. A previous
mouse study demonstrated alterations in the snoRNA profile of young compared with
old and OA compared with healthy controls in joints and serum, highlighting the
potential of snoRNAs to be used as novel markers for OA and aging.
In human cartilage, snoRNAs are differentially expressed due to aging
(including SNORD96A and SNORD44) and OA (including SNORD26 and SNORD116).
Altering SNORD26 or SNORD96A expression resulted in changes in chondrogenic-,
hypertrophic-, rRNA- and OA-related gene expression.
U3, one of the most abundant snoRNAs playing a key role in ribosome
biogenesis, was found to have significantly lower expression in human OA cartilage
and chondrocytes. The protein translational capacity of chondrocyte cultures with
diminished U3 snoRNA expression was significantly reduced, while ectopic induction
of U3 snoRNA expression resulted in increased translational capacity.
In the present study, we detected 17 downregulated snoRNAs in chondrocytes at
passage 5 compared with passage 0 (
). However, only ENSMUSG00000065904 was verified to be upregulated, which was
consistent with the sequencing results. The other 16 snoRNAs with upregulated
sequencing results were verified to have decreased expression.SnRNA is the main component of the RNA spliceosome in the posttranscriptional
processing of eukaryotes and participates in splicing pre-mRNA and noncoding
transcripts in cells. In humans, its length is approximately 60-330 nucleotides, and
it can be divided into 14 categories. U1-U7 are rich in uridylate. U3 snRNA is
related to the maturation of 28S rRNA in the nucleolus, while U1 is related to the
splicing and processing of precursor mRNA in the nucleus. Rn7SK is a highly
conserved snRNA transcribed by RNA polymerase III and is a regulator of Pol II
activity through inhibiting the function of positive transcriptional elongation
factor b. A recent study demonstrated that Rn7SK participates in the regulation of
cellular senescence, with the transient knockdown of Rn7SK in mesenchymal stem cells
(MSCs) leading to delayed senescence, while its overexpression shows the opposite effects.
However, the role of snRNA in chondrocytes and its relationship with OA have
not yet been reported. We found that the expression of snRNA ENSMUSG00000087754
increased and the other 9 snRNAs decreased at passage 5 (
). The function and potential targets of these snRNAs in chondrocytes will be
explored and verified in our subsequent studies. However, many sequencing results
for snoRNA and snRNA are inconsistent with the expression trends observed via
qRT-PCR. We speculate that there may be many stem-loop structures in snoRNA and
snRNA, which will affect the sequencing or qRT-PCR results.At present, the treatment of OA is still a clinical challenge, and the understanding
of the molecular mechanism is still unclear. SncRNAs are promising candidates for
targeted therapeutics in OA due to their small size, and their activity can be
modulated via small molecules and biological delivery systems.[15,16] However, the
study of sncRNAs in the aging process of chondrocytes is not sufficient.
Anti-senescence therapy is a frequently discussed clinical issue, and research into
this topic involves new drug research, drug-target protein detection, and disease
mechanism exploration. Through screening, we will be able to verify the target genes
of the above differentially expressed sncRNAs in subsequent in vivo
and in vitro studies. The sequencing results showed that rasiRNA
was differentially expressed in senescent chondrocytes. However, due to the scarcity
of research on rasiRNA and its short length, it is difficult to verify the
sequencing results by conventional real-time PCR. More studies are needed to explore
the role of rasiRNA in chondrocyte aging.
Conclusion
In this study, we detected the expression changes in miRNAs, piRNAs, snoRNAs, snRNAs
and repeat RNAs during chondrocyte aging by high-throughput small RNA sequencing and
detected the expression of miRNAs, piRNAs, snoRNAs, and snRNAs during chondrocyte
aging by qRT-PCR. We found that the expression of miRNA, piRNA, snoRNA, snRNA, and
repeat RNA changes significantly during chondrocyte aging and is tissue
specific.Click here for additional data file.Supplemental material, sj-xlsx-1-car-10.1177_19476035221118165 for Changes in
Small Noncoding RNA Expression during Chondrocyte Senescence by Fei Xiao,
Chenglong Wang, Jianping Peng, Xing Zhou, Ding Ma, Yu Wang, Yanpeng Li, Xiaodong
Chen and Chuandong Wang in CARTILAGE
Authors: Mandy J Peffers; Alzbeta Chabronova; Panagiotis Balaskas; Yongxiang Fang; Philip Dyer; Andy Cremers; Pieter J Emans; Peter Z Feczko; Marjolein M Caron; Tim J M Welting Journal: Sci Rep Date: 2020-06-30 Impact factor: 4.379
Authors: Panagiotis Balaskas; Jonathan A Green; Tariq M Haqqi; Philip Dyer; Yalda A Kharaz; Yongxiang Fang; Xuan Liu; Tim J M Welting; Mandy J Peffers Journal: Int J Mol Sci Date: 2020-08-07 Impact factor: 5.923